Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
Cyclospora parasite illnesses have affected 28 NC counties, sickened more than 200 people
Recommended
Back to school guide: Buses, lunches, key dates
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Apellis Pharmaceuticals Inc
(NQ:
APLS
)
37.25
-0.37 (-0.98%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Apellis Pharmaceuticals Inc
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Where Apellis Pharmaceuticals Stands With Analysts
July 18, 2023
Via
Benzinga
Why Are Apellis Pharmaceuticals Shares More Down 20% Today?
July 17, 2023
Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares are trading lower amid safety concerns regarding the company's newly launched Syfovre (pegcetacoplan injection) for geographic atrophy (GA) secondary...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
July 17, 2023
Via
Benzinga
Ford Motor, AT&T, Frontier Communications And Other Big Stocks Moving Lower On Monday
July 17, 2023
U.S. stocks traded higher, with the Dow Jones gaining over 50 points on Monday. Here are some big stocks recording losses in today’s session. Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) shares...
Via
Benzinga
Apellis Pharma Crashes After Safety Report Undercuts Its Newest Eye Drug
July 17, 2023
Now, investors are questioning the future for Apellis' Syfovre, an eye-disease treatment.
Via
Investor's Business Daily
The Latest Analyst Ratings for Apellis Pharmaceuticals
June 13, 2023
Via
Benzinga
Needham Maintains Buy Rating for Apellis Pharmaceuticals: Here's What You Need To Know
May 05, 2023
Via
Benzinga
Top-Notch Biotech Apellis Soars After New Drug Obliterates Sales Views
May 05, 2023
The company easily beat sales calls on the back of Syfovre, a geography atrophy drug.
Via
Investor's Business Daily
Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
July 17, 2023
Gainers ProMIS Neurosciences, Inc. (NASDAQ: PMN) shares jumped 126.6% to $6.37. ProMIS showcased preclinical data at the Alzheimer's Association International Conference 2023 on computationally-derived...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
July 17, 2023
Via
Benzinga
Why BYND Cannasoft Enterprises Shares Are Trading Lower By 40%; Here Are 20 Stocks Moving Premarket
July 17, 2023
Gainers
Via
Benzinga
The Latest Analyst Ratings for Apellis Pharmaceuticals
May 05, 2023
Via
Benzinga
Apellis Pharmaceuticals: Q1 Earnings Insights
May 04, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
July 17, 2023
It's time to start off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday!
Via
InvestorPlace
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
June 02, 2023
Big Pharma is facing a patent cliff that could siphon off billions in revenue.
Via
Investor's Business Daily
Apellis Pharma Flunks On Primary, Secondary Endpoints In Amyotrophic Lateral Sclerosis Study
May 25, 2023
Via
Benzinga
Why Shares of Annexon Are Plummeting Thursday
May 25, 2023
Mixed trial results on a geographic atrophy eye drug led investors to sell the biotech stock.
Via
The Motley Fool
Earnings Preview: Apellis Pharmaceuticals
May 03, 2023
Via
Benzinga
Wedbush Maintains Neutral Rating for Apellis Pharmaceuticals: Here's What You Need To Know
April 17, 2023
Via
Benzinga
9 Analysts Have This to Say About Apellis Pharmaceuticals
April 14, 2023
Via
Benzinga
Why These 3 Nasdaq Stocks Buckled Today
May 16, 2023
The FTC's decision to sue to block a high-profile merger is weighing on biotech valuations today.
Via
The Motley Fool
Apellis Pharma's Newly Approved Drug Exceeds Sales Projections, Bullish Analyst Raises Expectations
May 05, 2023
Apellis Pharmaceuticals Inc (NASDAQ: APLS) reported Q1 revenues of $44.8 million, surpassing the consensus of $26.10 million and
Via
Benzinga
Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today
May 01, 2023
These three biotech stocks were on the volatile side today.
Via
The Motley Fool
Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma
May 01, 2023
The company is working on a treatment for the eye disease known as geographic atrophy.
Via
Investor's Business Daily
Top 5 Health Care Stocks That Could Sink Your Portfolio This Quarter
April 27, 2023
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
Why Apellis Pharmaceuticals Stock Is Soaring Today
April 03, 2023
Rare disease-focused Apellis Pharmaceuticals Inc (NASDAQ: APLS) is reportedly drawing takeover interest from large drugmakers.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
April 26, 2023
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
April 19, 2023
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
April 12, 2023
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
April 03, 2023
Via
Benzinga
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.